GlassScriptPhysician profile
Robert P Holfelder
NPI 1477595148
$1,104.90
in general payments reported to CMS, 2019-2025
25 companies · $14.07 in 2025
The $14.07 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $514 · 2022: $136 · 2023: $282 · 2024: $160 · 2025: $14.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $455.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $397.21 | 2021-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $108.20 | 2021-2023 | Breztri |
| Merck Sharp & Dohme LLC | $82.44 | 2021 | |
| Pfizer INC. | $63.49 | 2021-2022 | |
| Amarin Pharma, INC. | $54.56 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.51 | 2021 | |
| Astellas Pharma US INC | $36.73 | 2023-2024 | Veozah |
| Lilly USA, LLC | $29.56 | 2021-2023 | Mounjaro |
| Silk Road Medical, INC. | $25.06 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Aimmune Therapeutics, INC. | $23.53 | 2024 | |
| Renalytix Ai, INC. | $23.47 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Xeris Pharmaceuticals, INC. | $19.09 | 2023 | Keveyis |
| Noven Therapeutics, LLC | $18.29 | 2023 | Xelstrym |
| Eisai INC. | $17.49 | 2021 | |
| Abbvie INC. | $17.47 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $16.82 | 2024 | |
| Scilex Pharmaceuticals INC. | $16.60 | 2023 | Ztlido |
| Glaxosmithkline, LLC. | $15.98 | 2023 | Shingrix, Arexvy |
| Hologic Sales and Service, LLC | $15.71 | 2023 | Thinprep 2000 Processor, Aptima |
| Noven Pharmaceuticals, INC. | $14.64 | 2023 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $14.24 | 2023 | Quviviq |
| Amgen INC. | $14.07 | 2025 | Repatha |
| Phathom Pharmaceuticals, INC. | $13.41 | 2024 | Voquezna |
| Daiichi Sankyo INC. | $13.32 | 2022 | |
| Almatica Pharma LLC | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Holfelder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.